Cited 0 times in
Long-term results of topical 0.02% tacrolimus ointment for refractory ocular surface inflammation in pediatric patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김태임 | - |
dc.contributor.author | 서경률 | - |
dc.contributor.author | 전익현 | - |
dc.date.accessioned | 2021-12-28T17:11:56Z | - |
dc.date.available | 2021-12-28T17:11:56Z | - |
dc.date.issued | 2021-06 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/186983 | - |
dc.description.abstract | Background: No studies have been reported on the efficacy and safety of long-term (≥12 months) use of topical tacrolimus for refractory ocular surface inflammation in pediatric patients. Methods: Medical records of pediatric patients who were prescribed topical 0.02% tacrolimus ointment for refractory ocular surface inflammation between January of 2010 and March of 2018 were reviewed retrospectively. Changes in ocular surface signs during slit-lamp examination, clinical symptoms and concurrent steroid use were graded with a scoring system. The presence of side effects was also assessed. The changes in disease severity and patient symptoms were compared between baseline and after the treatment. Results: Among 72 patients (55% males, mean age 10.8 ± 3.9 years, range 3 to 17 years), 25 patients (48% males, mean age 11.4 ± 3.9 years) fully recovered, resulting in discontinuance of the ointment treatment before 12 months. Six patients experienced intolerable burning sensation, which required treatment cessation. Cessation days of those who quit were 1,5,14,20,26, and 35 days. Seven patients were lost during follow-up. Thirty-four patients (56% males, mean age 11.2 ± 4.2 years, range 3 to 17 years) were treated with tacrolimus ointment for over 12 months (average 23.1 ± 19.1 months, range 12 to 98 months). During the follow-up period, all patients showed improved clinical signs and symptoms, and no adverse reaction was noted. Conclusions: Long-term maintenance of topical tacrolimus 0.02% ointment is safe and effective in improving refractory ocular surface inflammation in pediatric patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | BioMed Central | - |
dc.relation.isPartOf | BMC OPHTHALMOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Child | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunosuppressive Agents* | - |
dc.subject.MESH | Infant | - |
dc.subject.MESH | Inflammation | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Ointments | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Tacrolimus* | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Long-term results of topical 0.02% tacrolimus ointment for refractory ocular surface inflammation in pediatric patients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Ophthalmology (안과학교실) | - |
dc.contributor.googleauthor | Kyungmin Koh | - |
dc.contributor.googleauthor | Ikhyun Jun | - |
dc.contributor.googleauthor | Tae-Im Kim | - |
dc.contributor.googleauthor | Eung Kweon Kim | - |
dc.contributor.googleauthor | Kyoung Yul Seo | - |
dc.identifier.doi | 10.1186/s12886-021-01998-0 | - |
dc.contributor.localId | A01080 | - |
dc.contributor.localId | A01870 | - |
dc.contributor.localId | A03541 | - |
dc.relation.journalcode | J00370 | - |
dc.identifier.eissn | 1471-2415 | - |
dc.identifier.pmid | 34088281 | - |
dc.subject.keyword | Pediatric patient | - |
dc.subject.keyword | Refractory ocular surface inflammation | - |
dc.subject.keyword | Topical tacrolimus | - |
dc.contributor.alternativeName | Kim, Tae Im | - |
dc.contributor.affiliatedAuthor | 김태임 | - |
dc.contributor.affiliatedAuthor | 서경률 | - |
dc.contributor.affiliatedAuthor | 전익현 | - |
dc.citation.volume | 21 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 247 | - |
dc.identifier.bibliographicCitation | BMC OPHTHALMOLOGY, Vol.21(1) : 247, 2021-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.